Over the last 30 years, several epidemiological and prospective studies have identified a number of risk factors for the development of cardiovascular disease. Lipid abnormalities are central among these risk factors, and their correction has been a major target for the medical community. The 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG-CoA reductase) inhibitors (statins) are the most widely prescribed and best tolerated of the currently available lipid-modifying therapies. Newer agents in this class (e.g. rosuvastatin) have been developed that have proven to be more effective at lowering levels of low-density lipoprotein cholesterol (LDL-C). New formulations of drugs such as nicotinic acid can improve treatment regimens and reduce unpleasant side-effects, thereby improving patient compliance with this therapy. In terms of developing novel drugs, the introduction of cholesterol absorption inhibitors (e.g. ezetimibe) and ACAT inhibitors (e.g. avasimibe) will provide clinicians with therapies that exploit different therapeutic pathways to those currently being utilised. Combining these agents with statins could produce greater improvements in lipid profile than those seen to date. In addition, advances in our understanding of the pathophysiology of dyslipidaemia have led to the identification of other novel therapeutic targets, including cholesteryl ester transfer protein. Studies with experimental drugs have already demonstrated the potential of these approaches.

Keywords:
Cardiovascular disease, Cholesterol absorption, Combination therapy, Low-density lipoprotein, Statin
1.
Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K: Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434–1503.
2.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;16:2486–2497.
3.
Maron DJ, Fazio S, MacRae FL: Current perspectives on statins. Circulation 2000;101:207–213.
4.
EUROASPIRE II Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II. Eur Heart J 2001;22:554–572.
5.
Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
6.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301–1307.
7.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–1009.
8.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615–1622.
9.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.
10.
Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999;341:498–511.
11.
Davidson M, Ma P, Stein E, Hutchinson HG, Caplan R, Raza A, Gotto A: Rosuvastatin is more effective than atorvastatin at improving the lipid profiles of patients with primary hypercholesterolaemia. Atherosclerosis Suppl 2001;2:38.
12.
Paoletti R, Fahmy M, Mahla G, Caplan R, Raza A: Rosuvastatin is more effective than pravastatin or simvastatin at improving the lipid profiles of hypercholesterolaemic patients. Atherosclerosis Suppl 2001;2:87.
13.
Kajinami K, Koizumi J, Ueda K, Miyamoto S, Takegoshi T, Mabuchi H, for the Hokuriku NK-104 study group: Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am J Cardiol 2000;85:178–183.
14.
Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88:504–508.
15.
Insull W, Koren M, Davignon J, Sprecher D, Schrott H, Keilson LM, Brown AS, Dujovne CA, Davidson MH, McLain R, Heinonen T: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 2001;157:137–144.
16.
Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke SK: Colesevelam hydrochloride (Cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893–1900.
17.
Knopp RH, Gitter H, Truitt T, Lipka LJ, LeBeaut AP, Suresh R, Veltri EP: Ezetimibe reduces low-density lipoprotein cholesterol: Results of a phase III, randomised, double-blind, placebo-controlled trial. Atherosclerosis Suppl 2001;2:38.
18.
Saito Y, Goto Y, Japan Itavastatin Clinical Study Group: Efficacy and safety of NK-104 (itavastatin) in hyperlipidemic subjects: A double-blind comparative study. Atherosclerosis 2000;151:154.
19.
Kashyap ML, Evans R, Simmons PD, Kohler RM, McGovern ME: New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated. J Am Coll Cardiol 2000;35(suppl a):326.
20.
Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, Donovan JM, Burke SK: Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001;24:467–474.
21.
Hunninghake DB, Chitra RR, Simonson SG, Schneck DW: Treatment of hypertriglyceridemic patients with rosuvastatin. Diabetes 2001;50(suppl 2):A143.
22.
Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, Burrows E, Retzlaff B, Poole M: Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism 1985;34:642–650.
23.
Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–381.
24.
Knopp RH: Evaluating niacin in its various forms. Am J Cardiol 2000;86(suppl 1):51–56.
25.
Garg A, Grundy SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723–726.
26.
Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J: Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. Am J Cardiol 1998;82:74U–81U.
27.
Goldberg A, Alagona P Jr, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, Sachson R, Samuel P: Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100–1105.
28.
Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina S: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097–1104.
29.
Wolfe ML, Vartanian SF, Ross JL, Bansavich LL, Mohler ER 3rd, Meagher E, Friedrich CA, Rader DJ: Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001;87:476–479.
30.
Tavintharan S, Kashyap ML: The benefits of niacin in atherosclerosis. Curr Atheroscler Rep 2001;3:74–82.
31.
Hiatt JG, Shamsie SG, Schectman G: Discontinuation rates of cholesterol-lowering medications: Implications for primary care. Am J Manag Care 1999;5:437–444.
32.
Davidson MH, Dicklin MR, Maki KC, Kleinpell RM: Colesevelam hydrochloride: A non-absorbed, polymeric cholesterol lowering agent. Expert Opin Investig Drugs 2000;9:2663–2671.
33.
Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, Davidson MH: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352–360.
34.
Hara S, Higaki J, Higashino K, Iwai M, Takasu N, Miyata K, Tonda K, Nagata K, Goh Y, Mizui T: S-8921, an ileal Na+/bile acid cotransporter inhibitor decreases serum cholesterol in hamsters. Life Sci 1997;60:365–370.
35.
Ichihashi T, Izawa M, Miyata K, Mizui T, Hirano K, Takagishi Y: Mechanism of hypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile acid absorption. J Pharmacol Exp Ther 1998;284:43–50.
36.
Higaki J, Hara S, Takasu N, Tonda K, Miyata K, Shike T, Nagata K, Mizui T: Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998;18:1304–1311.
37.
Kesaniemi YA, Miettinen TA: Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 1987;17:391–395.
38.
Best MM, Duncan CH, Van Loon EJ, Wathen JD: Lowering of serum cholesterol by the administration of a plant sterol. Circulation 1954;10:201–206.
39.
Heinemann T, Kullak-Ublick A, Pietruk B, von Bergmann K: Mechanisms of action of plant sterols on inhibition of cholesterol absorption. Eur J Clin Pharmacol 1991;40(suppl 1):59S–63S.
40.
Neil HA, Meijer GW, Roe LS: Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis 2001;156:329–337.
41.
Law M: Plant sterol and stanol margarines and health. BMJ 2001;320:861–864.
42.
Nigon F, Serfaty-Lacronière C, Beucler I, Chauvois D, Neveu C, Giral P, Chapman MJ, Bruckert E: Plant sterol-enriched margarine lowers plasma LDL-C in hyperlipidemic subjects with low cholesterol intake: Effects of fibrate treatment. Clin Chem Lab Med 2001;39:634–640.
43.
Hernandez M, Montenegro J, Steiner M, Kim D, Sparrow C, Detmers PA, Wright SD, Chao YS: Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter. Biochim Biophys Acta 2000;1486:232–242.
44.
Detmers PA, Patel S, Hernandez M, Montenegro J, Lisnock JM, Pikounis B, Steiner M, Kim D, Sparrow C, Chao YS, Wright SD: A target for cholesterol absorption inhibitors in the enterocyte brush border membrane. Biochim Biophys Acta 2000;20:243–252.
45.
Brown WV: Novel approaches to lipid lowering: What is on the horizon? Am J Cardiol 2001;87(suppl 1):23–27.
46.
Lipka LJ, LeBeaut AP, Veltri EP, Mellars LE, Bays HL, Moore PB: Reduction of LDL-C and elevation of HDL-C in subjects with primary hypercholesterolemia by SCH 58235: Pooled analysis of two phase II studies. J Am Coll Cardiol 2000;35(suppl a):257A.
47.
Bocan TMA, Krause BR, Rosebury WS, Mueller SB, Lu X, Dagle C, Major T, Lathia C, Lee H: The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000;20:70–79.
48.
Azuma Y, Kawasaki T, Ikemoto K, Obata K, Ohno K, Sajiki N, Yamada T, Yamasaki M, Nobuhara Y: Cholesterol-lowering effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits. Jpn J Pharmacol 1998;78:355–364.
49.
Junquero D, Bruniquel F, N’Guyen X, Autin JM, Patoiseau JF, Degryse AD, Colpaert FC, Delhon A: F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. Atherosclerosis 2001;155:131–142.
50.
Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835–2838.
51.
Abbott RD, Wilson PWF, Kannel WB, Castelli WP: High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: The Framingham study. Arteriosclerosis 1988;8:207–211.
52.
Kane J: Structure and function of the plasma lipoproteins and their receptors; in Fuster V, Ross R, Topol EJ (eds): Atherosclerosis and Coronary Artery Disease. Philadelphia, Lippincott-Raven, 1996, vol 1, pp 89–103.
53.
Tall A, Breslow J: Plasma high-density lipoproteins and atherogenesis; in Fuster V, Ross R, Topol EJ (eds): Atherosclerosis and Coronary Artery Disease. Philadelphia, Lippincott-Raven, 1996, vol 1, pp 105–362.
54.
Banka CL: High density lipoprotein and lipoprotein oxidation. Curr Opin Lipidol 1996;7:139–142.
55.
Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996;20:707–727.
56.
Barter PJ, Rye KA: High density lipoproteins and coronary heart disease. Atherosclerosis 1996;121:1–12.
57.
Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW: A-I Milano apoprotein: Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66:892–900.
58.
Franceschini G, Vecchio G, Gianfranceschi G, Magani D, Sirtori CR: Apolipoprotein A-I Milano: Accelerated binding and dissociation from lipids of a human apolipoprotein variant. J Biol Chem 1985;260:16321–16325.
59.
Bruckert E, von Eckardstein A, Funke H, Beucler I, Wiebusch H, Turpin G, Assmann G: The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-I Milano. Atherosclerosis 1997;128:121–128.
60.
Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B: Effects of recombinant apolipoprotein A-I Milano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 1998;97:780–785.
61.
Franceschini G, Calabresi L, Chiesa G, Parolini C, Sistori CR, Canavesi M, Bernini F: Increased cholesterol efflux potential of sera from Apo A-I Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 1999;19:1257–1262.
62.
Tall AR: Plasma lipid transfer proteins. Annu Rev Biochem 1995;64:235–257.
63.
Rong JX, Fisher EA: High-density lipoprotein: Gene-based approaches to the prevention of atherosclerosis. Ann Med 2000;32:642–651.
64.
Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR: Increased high-density lipoprotein levels caused by a common cholesteryl ester transfer protein gene mutation. N Engl J Med 1990;323:1234–1238.
65.
Bruce C, Sharp DS, Tall AR: Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998;39:1071–1078.
66.
Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR: Increased atherosclerosis in ApoE and LDL receptor knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999;19:1105–1110.
67.
Shinkai H, Maeda K, Yamasaki T, Okamoto H, Uchida I: bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J Med Chem 2000;43:3566–3572.
68.
Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203–207.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.